Safety of rivaroxaban in elderly patients

Abstract

Diseases associated with blood clotting disorders are one of the most common problems of a modern person and, accordingly, of the attending physician. Since apixaban is the drug of choice for the treatment of thrombosis and prevention of strokes and embolism, the practitioner needs to be aware of the pharmacological properties and safety of apixaban in special groups of patients. This article provides updated information on the safety of apixaban in patients with kidney disease. We identified potentially relevant studies by searching the electronic databases MEDLINE, Scopus, PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews from January 2022 to November 2023 using the terms: apixaban, anticoagulants,thrombosis, stroke, embolism, kidney disease, chronic kidney disease, therapy, safety, efficacy,adverse effects, clinical trials. Then, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources meeting the criteria and compiled this review. Recent data show high safety of apixaban, supporting its use as a first-line treatment for thrombosis in patients with kidney diseases.